Pharmaceutical

CT-080 by First Condor Group for Gastric Cancer: Likelihood of Approval

CT-080 is under clinical development by First Condor Group and currently in Phase II for Gastric Cancer.

Oct 3, 2023 - 20:00
CT-080 is under clinical development by First Condor Group and currently in Phase II for Gastric Cancer.
Read the original article

Tags:

Previous Article

CT-080 by First Condor Group for Solid Tumor: Likelihood of Approval

Next Article

New study reveals Australian Long COVID response lagging

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future

Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex...

Dec 15, 2023

Sutro strengthens its immuno-oncology pipeline with two new ADCs

Sutro strengthens its immuno-oncology pipeline with two...

Aug 12, 2023

Revised EU/Pfizer/BioNTech Covid-19 vaccine deal may lead to a Comirnaty monopoly

Revised EU/Pfizer/BioNTech Covid-19 vaccine deal may le...

Jun 3, 2023